Sales & Marketing

Vickie Andros and Jake Caines discuss how to identify and overcome barriers that keep prescriptions from getting to the pharmacy, and most importantly, to the patient.

But how much better would our creative be if we took the time to really listen to what our clients are saying – and what they are not saying – rather than reading between the lines of an RFP?

Shared understanding of both risks and benefits to all parties in the healthcare continuum is essential in order to deliver more value, write Vickie Andros and Jake Caines.

This post highlights the benefits of a new IT favorite for healthcare marketing, trigger emails.

Consumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Organizations and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan, writes John Pagliuca.

Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.

Innovation by itself won't solve the complex multichannel challenges pharmas face.

Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.

Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.

Organizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.

The internet giant’s latest service may also be another piece of the company’s pharma puzzle.

Healthcare companies are overwhelming physicians and hospitals with brand messaging overlap. Let’s use data science to fix that, says Kevin Troyanos.

This article discusses email marketing opportunities through the lens of 1999's dramatic comedy, She's All That.

To get their messages out in this age of polarisation and "too much information", marketers need to shout louder, have a more dramatic point of view and gather a league of similar advocates to succeed. Al Topin sees the solution in common sense and courage.

Pharm Exec’s 13th Annual Press Audit audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.

For the life sciences industry in 2017, engaging across social media means less talking-and more listening.

The era of complex biological drugs requires sales reps with more advanced knowledge, write Barat Lalayan.

Gregg Fisher reflects on how this brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.

With healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging-or create their own.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian.

Experts say knowing how to lead in uncertain times and being open to change is just as important as a degree.